TransMedics (TMDX) Cash & Equivalents (2018 - 2026)

TransMedics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $461.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 48.87% year-over-year to $461.7 million; the TTM figure through Mar 2026 stood at $461.7 million (up 48.87% YoY), while the FY2025 annual figure was $488.4 million, up 45.07% from the prior year.
• Cash & Equivalents was $461.7 million for Q1 2026 at TransMedics, down from $488.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $582.2 million in Q2 2023 to a low of $17.9 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $329.2 million across 5 years, with a median of $350.2 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents surged 1816.01% in 2023, then sank 37.69% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $201.2 million in 2022, then surged by 96.25% to $394.8 million in 2023, then fell by 14.73% to $336.6 million in 2024, then jumped by 45.07% to $488.4 million in 2025, then fell by 5.46% to $461.7 million in 2026.
• The last three Cash & Equivalents figures came in at $461.7 million (Q1 2026), $488.4 million (Q4 2025), and $466.2 million (Q3 2025), per Business Quant data.